(European Society of Cardiology) Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, lowers the risk of heart attack and related cardiovascular complications in patients receiving intensive statin treatment, according to late-breaking results from the REVEAL trial presented today in a Hot Line Session at ESC Congress and published in the NEJM.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2wOxx95
No comments:
Post a Comment